| Online-Ressource |
Verfasst von: | Chekerov, Radoslav [VerfasserIn]  |
| Wischnik, Arthur [VerfasserIn]  |
Titel: | Treosulfan in the treatment of advanced ovarian cancer |
Titelzusatz: | results of a German multicenter non-interventional study |
Verf.angabe: | Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach and Jalid Sehouli |
E-Jahr: | 2015 |
Jahr: | December 2015 |
Umfang: | 7 S. |
Fussnoten: | Gesehen am 29.11.2018 |
Titel Quelle: | Enthalten in: Anticancer research |
Ort Quelle: | Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |
Jahr Quelle: | 2015 |
Band/Heft Quelle: | 35(2015), 12, Seite 6869-6875 |
ISSN Quelle: | 1791-7530 |
Abstract: | Background: Data on routine systemic treatment of patients with ovarian cancer are currently available only to a limited degree. The alkylating agent treosulfan is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of ovarian carcinoma. The present non-interventional study analyzed the clinical use of treosulfan in Germany, evaluating the mode of application, toxicity, and response and survival rate. Patients and Methods: Two hundred and forty-eight ovarian cancer patients in 57 Centers, who received treosulfan mainly either i.v. (5,000-8,000 mg/m2 d1, q21d or q28d) or p.o. (400-600 mg/m2 d1-14 or 21, q28d) for at least one therapy cycle were evaluable and were included in the study. Results: With a median age of 70 years (range=36-92 years), predominantly elderly patients received treosulfan treatment. Most participants presented serous histology (131, 52.8%) and advanced-stage FIGO III (122, 49%) or IV (55, 22%) disease. Median ECOG status was 1 (range=0-2), whereas cardiac co-morbidity was common (31%). Treosulfan was usually administered as second- (26%), third- (21%) or fourth-line (17%) therapy. Two hundred and one patients received i.v. and 47 p.o. treatment. The most common reason for dose modifications was due to hematological toxicity (46%). The main reason for a therapy discontinuation was progressive disease (38.5%). Response was observed in 25.8% of participants, disease stabilization in 28.6 % and progress in 45.6%. The median progression-free and overall survival was 196 and 405 days, respectively. Conclusion: In predominantly elderly and heavily pre-treated patients with recurrent ovarian cancer, treosulfan featured a clinical relevant efficacy and well-manageable, mostly hematological, toxicity, which resulted in a positive therapeutic index. |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/undefined |
| Volltext: http://ar.iiarjournals.org/content/35/12/6869 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | elderly |
| non-interventional study |
| ovarian cancer |
| Treosulfan |
K10plus-PPN: | 1584620013 |
Verknüpfungen: | → Zeitschrift |
Treosulfan in the treatment of advanced ovarian cancer / Chekerov, Radoslav [VerfasserIn]; December 2015 (Online-Ressource)